EUVIMEDOpdag EUVIMED
Crossref

CCR2/CCR5 antagonist cenicriviroc reduces colonic inflammation and fibrosis in experimental colitis

Xin Song, Chensheng Jiang, Mengli Yu, Chao Lu, Xinjue He iD

Journal of Gastroenterology and Hepatology · 2024

DOI: 10.1111/jgh.16622 ↗

At a glance

Journal article in Journal of Gastroenterology and Hepatology, 2024. Written by Xin Song and 4 co-authors. Institution: Department of Gastroenterology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. Major MEDLINE topics: Colitis, Disease Models, Animal, Receptors, CCR2, Fibrosis. Cited 14 times so far (Crossref); 22 references. Funded by: Fundamental Research Funds for the Central Universities, Zhejiang Provincial Natural Science Foundation of China, National Natural Science Foundation of China.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background and Aim Cenicriviroc (CVC) is a CCR2/CCR5 antagonist that has been shown to be effective in the treatment of inflammatory and fibrotic diseases. Our study evaluated its efficacy in colitis.

Methods

Mouse models of DSS‐induced acute and chronic colitis were established. The efficacy of CVC in colitis was assessed by disease activity index (DAI) scores, histological assessment of inflammation and fibrosis, and expression assays of key molecules. In in vitro experiments, HT29 cell line was exposed to TNFα to study inflammatory signaling in intestinal epithelial cells. CCD‐18Co colonic myofibroblasts and human primary colonic fibroblasts were activated by TGFβ1 to mimic fibroblast activation.

Results

In HT29 cells, CVC significantly reduced mRNA expression of CCL5 ( P < 0.01) but had no effect on CCL2. Furthermore, CVC reduced downstream CX3CL1 ( P < 0.01) and TNFα ( P < 0.05) expression, thereby inhibiting inflammatory progression. In acute colitis mice, CVC significantly reduced DAI scores and serum TNFα levels ( P < 0.05) and attenuated colonic inflammation as shown by HE staining. Meanwhile, CVC had no adverse effects on the liver, heart, and kidney of mice. On the other hand, in cellular models of chronic colitis, CVC decreased the expression of fibrosis markers, including FN, CTGF, α‐SMA, and MMP9, and inhibited TGFβ1‐induced fibrotic activation ( P < 0.01). In addition, CVC attenuated colonic fibrosis in chronic colitis mice. Moreover, CVC significantly promoted autophagy, which contributed to its regulation of inflammation.

Conclusions

CVC significantly inhibited inflammation through CCL5/CCR5 signaling without damaging vital organs and suppressed fibrotic activation in chronic colitis, suggesting its great potential to relieve colonic inflammation and fibrosis.

Subjects

MeSH terms (MEDLINE)

ColitisDisease Models, AnimalReceptors, CCR2FibrosisCCR5 Receptor AntagonistsColonAnimalsHumansReceptors, CCR5HT29 CellsTumor Necrosis Factor-alphaMiceMaleChemokine CCL5Mice, Inbred C57BLChronic DiseaseDextran SulfateImidazolesSulfoxides

Author keywords

CCR2CCR5cenicriviroccolitis

Substances

cenicrivirocReceptors, CCR2CCR5 Receptor AntagonistsReceptors, CCR5Tumor Necrosis Factor-alphaCcr2 protein, mouseChemokine CCL5CCR5 protein, mouseDextran SulfateImidazoles

Authors and institutions

  • Department of Gastroenterology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • Department of Gastroenterology, The Fourth Affiliated Hospital, Zhejiang University School of Medicine, Yiwu, China.

ORCID profiles: Xinjue He

Funding

  • Fundamental Research Funds for the Central Universities
  • Zhejiang Provincial Natural Science Foundation of China
  • National Natural Science Foundation of China

Cite

APA

Song, X., Jiang, C., Yu, M., Lu, C., & He, X. (2024). CCR2/CCR5 antagonist cenicriviroc reduces colonic inflammation and fibrosis in experimental colitis. Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/jgh.16622

Vancouver

Song X, Jiang C, Yu M, Lu C, He X. CCR2/CCR5 antagonist cenicriviroc reduces colonic inflammation and fibrosis in experimental colitis. Journal of Gastroenterology and Hepatology. 2024. doi:10.1111/jgh.16622

BibTeX
@article{Song2024,
  author = {Song, Xin and Jiang, Chensheng and Yu, Mengli and Lu, Chao and He, Xinjue},
  title = {CCR2/CCR5 antagonist cenicriviroc reduces colonic inflammation and fibrosis in experimental colitis},
  journal = {Journal of Gastroenterology and Hepatology},
  year = {2024},
  doi = {10.1111/jgh.16622}
}
Start for free →